Name: UMIN ID:
Unique ID issued by UMIN | UMIN000008470 |
---|---|
Receipt number | R000009626 |
Scientific Title | Post remission therapy with arsenic trioxide and gemtuzumab ozogamicin in acute promylocytic leukemia, a phase II study (JALSG APL212 Study) |
Date of disclosure of the study information | 2012/07/19 |
Last modified on | 2023/01/26 15:20:50 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2012/07/19 11:17:13 | ||
2 | Update | 2018/02/20 11:09:48 | Email Organization Address Address TEL Name of primary person or sponsor Organization Category of Funding Organization |
|
3 | Update | 2018/02/20 11:17:18 | Division name Division name |
|
4 | Update | 2023/01/26 15:14:23 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization1 Organization Organization Address Address Tel |
|
5 | Update | 2023/01/26 15:20:50 | Date of IRB Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |